A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

Phase 1/2 Recruiting 62 enrolled Kriya Therapeutics, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary to age-related macular degeneration (AMD).

Timeline

Start: 2025-05-28
Primary completion: 2027-12-15
Completion: 2027-12-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VV-14295	Gene therapy (AAV / viral vector)	—	Other

A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

Summary

Timeline

Drugs

Indications